Ximi Elga


Enbrel® (etanercept) is a prescription medicine used to treat five chronic diseases, including moderate to severe rheumatoid arthritis. These highlights do not include all the information needed to use Enbrel safely and effectively. See full prescribing information for Enbrel. Enbrel® (etanercept). What is Enbrel (etanercept) and what is it used for? of Product Characteristics ( SPC) for Enbrel these can be found at the electronic Medicines Compendium.

Author: Meztigor Fejora
Country: Trinidad & Tobago
Language: English (Spanish)
Genre: Literature
Published (Last): 10 June 2006
Pages: 359
PDF File Size: 3.23 Mb
ePub File Size: 19.76 Mb
ISBN: 282-4-19808-964-2
Downloads: 93956
Price: Free* [*Free Regsitration Required]
Uploader: Fenriramar

Enbrel 25 mg powder and solvent for solution for injection

Enter email address Submit. In postmarketing reports, serious infections have been reported. Consequently, the choice of intermittent or continuous therapy should be based upon physician judgment and individual patient needs. Additionally, studies have not been conducted to assess the effects of discontinuing or reducing the recommended dose of Enbrel following its long-term use in patients with JIA. Enbgel, the occurrence was rare, and the follow-up period of placebo patients was shorter than for patients receiving TNF-antagonist therapy.

The recommended dose of Enbrel is 25 mg administered twice weekly or 50 mg administered once weekly. Spx data from treating patients infected with HBV with anti-viral therapy in conjunction with TNF-antagonist therapy are not available.

In controlled trials in patients with plaque psoriasis, approximately Clearance is approximately 0. In some cases, particular fungal and other opportunistic infections have not been recognised, resulting in delay of appropriate treatment and sometimes death. The safety and efficacy enbrep of the 50 mg once-weekly and 25 mg twice-weekly regimens were similar. A total of patients were enrolled, from which were treated with Enbrel. Double-Blind Clinical Responses at Week Enbrel 25 mg powder and solvent for solution for injection.

Enbrel is reconstituted with 1 ml water for injections before use, and administered by subcutaneous injection. Clinical improvement, including xpc of action within 2 weeks with Enbrel 25 mg, was similar to that seen in the previous trials and enbrl maintained for up to 24 months.


Posology and administration are the same as for adults years of age. Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into consideration that the mean elimination half-life of etanercept is approximately 70 hours range 7 to hours. Instead, the safety and efficacy of Enbrel were assessed in sspc randomised, double-blind, placebo-controlled studies.

The International Conference on Harmonization Q5C provides guidance to applicants regarding the type of stability studies to be provided in support of marketing authorization applications and amendments for biologic medicinal products. If you have any questions about this information, be sure to discuss them with your healthcare provider.

Etanercept may also modulate biologic responses controlled by additional downstream molecules e. In a polyarticular-course juvenile idiopathic arthritis trial with Enbrel, 69 patients aged 4 to 17 years were administered 0. What did the researchers do and find? Etanercept contains amino acids and has an apparent molecular weight of approximately kilodaltons.

Enbrel® (etanercept)

In recent years, there has been a considerable change in the management of patients with RA. Reports have included fatal and life-threatening infections and sepsis. Footnotes Author contributions All the authors made substantial contributions to the conception and design, acquisition of data, and analysis and interpretation of data; were involved in drafting the manuscript and revising the manuscript critically for important intellectual content; and have given final approval of the version to be published.

Children and adolescents four to 17 years0. Etanercept 50 mg PFP DP The etanercept 50 mg PFP DP presentation is a spring-powered injection system consisting of two subassemblies, front and rear, enclosing a single etanercept 50 mg solution for injection in PFS, the contents of which are delivered to the patient subcutaneously.


Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light PUVA see section 5. These included abscess at various sitesbacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis, endocarditis suspectedgastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection, osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin infection, skin ulcer, urinary tract infection, vasculitis, and wound infection.

Explore a condition below. Enbrel treatment resulted in improvement in physical function during the double-blind period, and this benefit was maintained during the longer-term exposure of up to 2 years. A biexponential curve is required to describe the concentration time curve of etanercept. Clearance and volume estimates in patients aged 65 to 87 years were similar to estimates in patients less than 65 years of age.

In controlled clinical trials of etanercept across all indications, the frequency incidence proportion of interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0. The storage conditions at which stability tests were performed on the various etanercept DP presentations are summarized in Table 2.

Comprehensive instructions for the preparation and administration of the reconstituted Enbrel vial are given in the package leaflet, section 7, “Instructions for preparation and giving an injection of Enbrel. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. The International Conference on Dpc Q5C specifies the type of stability studies to be provided in support of marketing authorization for biologic products.